Cancer stem cells (CSCs) have been implicated in the maintenance and progression of several types of cancer. The origin and cellular properties of human CSCs are poorly characterized. Here we show that CSC-like cells can be generated in vitro by oncogenic reprogramming of human somatic cells during neoplastic transformation. We find that in vitro transformation confers stem-cell properties to primary differentiated fibroblasts, including the ability to self-renew and to differentiate along multiple lineages. Tumours induced by transformed fibroblasts are hierarchically organized, and the cells that act as CSCs to initiate and maintain tumour growth are marked by the stage-specific embryonic antigen SSEA-1. Heterogeneous lineages of cancer cells in the bulk of the tumour arise through differentiation of SSEA-1 + fibroblasts, and differentiation is associated with loss of tumorigenic potential. These findings establish an experimental system to characterize cellular and molecular properties of human CSCs and demonstrate that somatic cells have the potential to de-differentiate and acquire properties of CSCs.
In vitro generation of human cells with cancer stem cell properties
The cancer stem cell (CSC) hypothesis postulates that cancers are hierarchically organized and only a subset of cells, the CSCs, drive cancer growth 1, 2 . Defining features of putative CSCs are tumourinitiation potential, self-renewal capacity and the ability to differentiate into heterogeneous, non-tumorigenic cancer cells 1, 2 . Little is known about the cellular origin of CSCs. In some cancers, CSCs arise by transformation of adult stem cells [3] [4] [5] [6] . In addition, committed progenitors can acquire self-renewal ability and function as CSCs (refs 7, 8) . Whether differentiated somatic cells can aberrantly reprogramme and acquire CSC features is unclear.
CSCs have been implicated in the growth of several human cancers [9] [10] [11] [12] [13] [14] [15] [16] [17] , but the characterization of their biological properties has been hampered by the difficulty of isolating pure CSC populations and manipulating them ex vivo. The inability in CSC populations isolated from clinical samples to retrospectively identify the cell that suffered the first oncogenic hit and drove tumorigenesis has prevented direct comparison between a CSC and its non-neoplastic counterpart.
Human differentiated cells can be transformed in vitro by expression of telomerase (hTERT), the oncogenic H-RasV12 mutant and concomitant inhibition of p53 and pRB pathways by simian virus 40 (SV40) large T (LT) and small T (ST) antigens 18 . Such transformed cells nucleate tumours when injected into immunocompromised mice 18 . We demonstrate here that during in vitro transformation a subpopulation of fibroblasts reprogramme to a more primitive, multipotent cell type, which possesses all hallmarks of CSCs and generates hierarchically organized tumours.
RESULTS

In vitro -transformed fibroblasts acquire differentiation ability
We in vitro transformed primary skin fibroblasts by stably expressing hTERT, H-RasV12 and SV40 LT and ST antigens 18 ( Supplementary  Fig. S1a ) and examined tumours induced by the transformed cells in immunocompromised mice. In line with their mesenchymal origin, tumours lacked distinct differentiated structures, but were heterogeneous in their composition and contained cells with various morphologies (Fig. 1a , upper left panel). Immunohistochemical staining showed expression of markers of various lineages in tumours derived from transformed fibroblasts. Cells positive for endothelial (hCD34), muscle (myosin) and neural (β III-tubulin) markers were detected in several tumours (Fig. 1a) . Analysis by semiquantitative PCR with reverse transcription (RT-PCR) confirmed expression of markers of various lineages in tumours, whereas very low or undetectable levels were expressed in the transformed fibroblasts before injection (Fig. 1b) . No individual tumour expressed all markers, indicating that tumours induced by transformed fibroblasts did not have features of teratomas. These observations suggest that tumorigenic fibroblasts derived by in vitro transformation acquire the ability to differentiate along multiple lineages in vivo.
To directly demonstrate that the transformation process confers differentiation ability to somatic fibroblasts, we induced their differentiation in vitro along two distinct lineages. In contrast to hTERT-immortalized control fibroblasts, transformed cells from hTERT-1 diff.
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hMSC diff. two independent fibroblast cell lines efficiently differentiated into adipocytes and osteoblasts with similar efficiency to human mesenchymal stem cells (hMSCs; Fig. 1c-f ). Taken together, these results indicate that, during in vitro transformation, differentiated fibroblasts reprogramme into a less committed, more primitive cell type capable of differentiating along various lineages during tumour growth. This property is reminiscent of the ability of CSCs to generate intra-tumour heterogeneity by differentiating along various lineages.
We therefore explored the possibility that cells with CSC properties arise during transformation of differentiated fibroblasts.
SSEA-1 is a marker of tumorigenic in vitro -transformed cells
In hierarchically organized tumours, not all cells contribute equally to tumour growth, and only a distinct subset of cells, the CSCs, is tumorigenic 2, 19 . To identify potential markers of putative CSCs generated by in vitro transformation we probed for surface markers (Fig. 2a) . In contrast, the stage-specific embryonic antigen SSEA-1, an hES cell early differentiation marker 21 , previously identified as a CSC marker in human and mouse brain tumours 17, 22, 23 , was detected in ∼1% of transformed cells but was absent from primary and hTERT-immortalized cells (Fig. 2a,b and Supplementary  Fig. S2a ). Immunofluorescence microscopy confirmed the presence of SSEA-1 in ∼1% of transformed cells, whereas no positive cells were detected in the immortalized control population (Fig. 2c) . Similarly, ∼9% of in vitro-transformed mammary epithelial cells 24 were immunopositive for SSEA-1, whereas only ∼0.2% of SSEA-1 + cells were detected in primary cells (P < 0.001; Fig. 2d ), indicating that acquisition of SSEA-1 during in vitro transformation is not a unique property of fibroblasts. SSEA-1 + cells were also detected in clinical samples of fibrous tissue cancers, with SSEA-1 + cells present at varying abundances in 59% of the analysed tumours (n = 69; Fig. 2e ).
To rule out the possibility that rare, pre-existing stem cells in the population of primary cells are the source of SSEA-1 + cells, we infected primary fibroblasts with limiting amounts of viruses so that only ∼1:25,000 cells were infected with all three transforming factors. Under these conditions, the probability of infecting a rare stem cell present in the cell population is low ( Supplementary Fig. S2b ). Four randomly selected colonies of infected cells all contained SSEA-1 + cells and injection of two clones into immunocompromised mice resulted in tumour formation, indicating that SSEA-1 + cells do not arise from transformation of rare, pre-existing stem cells ( Fig. 2f and Supplementary Fig. S2b ). We conclude that the presence of the hES cell early differentiation marker SSEA-1 in populations of differentiated cells correlates with acquisition of tumorigenicity during transformation. These observations suggest SSEA-1 as a marker of putative CSCs generated by in vitro transformation.
Characterization of SSEA-1
+ -transformed fibroblasts A characteristic feature of stem cells is their ability to both self-renew and generate phenotypically distinct daughter cells 25, 26 . SSEA-1 + -sorted cells grown in culture rapidly generated a heterogeneous progeny with the percentage of SSEA-1 + cells in the population decreasing to that of the unsorted population in 6 days (Fig. 3a) . In agreement, immunofluorescence microscopy revealed that ∼21% of cell divisions resulted in one SSEA-1 + and one SSEA-1 − daughter cell, whereas ∼79% of divisions yielded two SSEA-1 + daughter cells (Fig. 3b ,c and Supplementary Fig. S3 fibroblasts by microarray analysis. ∼300 genes were differentially expressed in the two subsets of cells (Fig. 3f ). Amongst the most upregulated genes in SSEA-1 + fibroblasts were several involved in tumorigenesis and several cancer biomarkers, whereas many tumour suppressors were downregulated (Supplementary Table S1 ). Differences in the transcriptional profiles of SSEA-1 + and SSEA-1 − fibroblasts were not due to different expression levels of hTERT, H-RasV12 or SV40-T antigens ( Supplementary Fig. S1b ).
In vitro -generated SSEA-1 + fibroblasts are tumour initiators To test whether in vitro-generated SSEA-1 + cells have tumourinitiating capacity as predicted for CSCs, we carried out an in vivo lineage-tracking experiment to assess the relative contributions of SSEA-1 + and SSEA-1 − fibroblasts to tumour initiation in a model of competitive tumour development. SSEA-1 + cells from a green fluorescent protein (GFP)-labelled transformed fibroblast cell line and SSEA-1 − cells from an unlabelled line generated from the same parental line (see Methods) were co-xenografted and the percentage of GFP-labelled cells in the resulting tumours was evaluated (Fig. 4a) . As a positive control, when 100% of unsorted GFP-labelled transformed cells were injected, the vast majority of tumour cells were GFP + (89.3% ± 2.3; Fig. 4b ). When GFP-labelled SSEA-1 + cells were co-injected with competing unlabelled SSEA-1 − cells (28%:72%), four out of five tumours showed a high percentage of GFP-positive cells (76.1% ± 7.7) comparable to the positive control, whereas one tumour showed a lower fraction (30%; Fig. 4b ). Similarly, tumours derived from a mixed population of GFP-labelled SSEA-1 + fibroblasts and unlabelled non-tumorigenic hTERT-immortalized fibroblasts (28%:72%) contained mostly GFP + cells (87.7 ± 2.7%) (Fig. 4b ). These results demonstrate that SSEA-1 + fibroblasts are the cells primarily responsible for tumour development and contribute to most of the tumour mass, whereas SSEA-1 − fibroblasts are mostly non-tumorigenic. Immunohistochemical staining of tumour sections confirmed these results ( 
SSEA-1 + fibroblasts differentiate into heterogeneous, non-fibroblastic cancer cells
CSCs generate the bulk of a tumour by differentiating into heterogeneous, non-tumorigenic cancer cells 2, 19 . In line with differentiation of tumour-initiating SSEA-1 + fibroblasts, tumours originating from either unsorted or SSEA-1 + fibroblasts contained >90% of SSEA-1 − cells (Fig. 5a,b) . Furthermore, immunohistochemical staining of serial sections from tumours derived from GFP-labelled SSEA-1 + cells detected cells positive for endothelial (hCD34), muscle (myosin) and neural (β III-tubulin) markers in GFP-labelled areas (Fig. 5c ), indicating that GFP-labelled SSEA-1 + fibroblasts had differentiated into multiple cell types during tumour growth.
To demonstrate that single SSEA-1 + -transformed fibroblasts are multipotent, we examined tumours induced by clonally derived populations from SSEA-1 + -sorted cells. Tumours induced by three Fig. S5b,c ). In line with differentiation of transformed fibroblasts into other cell types during tumour growth, several mesenchymal markers were expressed at reduced levels in tumours. About 80% of tumour cells expressed lower levels of CD166 when compared with the injected fibroblasts, as assessed by FACS, and quantitative RT-PCR showed a ∼5-fold decrease in CDH2 and FGF2 expression (Fig. 5d-f) . Other markers such as CD29 and CD10 were unchanged, indicating that tumour cells do not lose all mesenchymal features (Fig. 5e) . Furthermore, on tumour dissociation only a minor percentage of cells (∼0.003%-1%, dependent on the number of injected cells) showed fibroblastic morphology and could be propagated in vitro in the same conditions as the injected fibroblasts (Fig. 5g) . We refer to these cells as tumour fibroblasts. Tumour fibroblasts expressed high levels of CD166, CDH2 and FGF2 and were positive for SSEA-1 ( Fig. 5d-f,h) . Conversely, SSEA-1 − cells from primary tumours were non-fibroblastic and expressed reduced levels of mesenchymal markers ( Fig. 5d and Supplementary Table S2 ). This observation highlights that tumour SSEA-1 − cells generated by differentiation of SSEA-1 + fibroblasts during tumour growth are a distinct cell state from the SSEA-1 − fibroblasts that arise during transformation. Taken together, these results demonstrate that SSEA-1 + in vitro-transformed fibroblasts are multipotent and generate tumour heterogeneity by differentiating into non-fibroblastic cells, as expected for CSCs.
SSEA-1
+ fibroblasts maintain hierarchically organized tumours A critical feature of CSCs is that they generate hierarchically organized tumours in which their progeny lose tumorigenic potential during differentiation and do not contribute to tumour maintenance. As a consequence, only a minor fraction of cells in a tumour are tumorigenic 2 . To assess whether in vitro-generated SSEA-1 + fibroblasts give rise to hierarchically organized tumours we estimated the number of tumorigenic cells in primary tumours. About 1:1,875 tumour cells were able to grow in soft agar and ∼1:5,000 cells were able to form spheres in suspension in low-adherence conditions, a common feature of various CSCs (ref. 27 ; Fig. 6a-c) . Furthermore, limiting dilution (Fig. 6d) . Thus, consistent with hierarchical organization, tumours induced by in vitro-transformed fibroblasts contain only a small fraction of tumorigenic cells, which maintain tumour growth. To assess whether it is the multipotent SSEA-1 + cells that sustain tumour growth rather than the differentiated SSEA-1 − cells, we isolated SSEA-1 + and SSEA-1 − cells from primary tumours and assessed their tumorigenic potential. Whereas ∼1:1,250 and ∼1:5,000 SSEA-1 + tumour cells were clonogenic in soft-agar and sphere-formation assays, respectively, SSEA-1 − cells did not form colonies in either condition (Fig. 6b,c) . In agreement, the numbers of tumorigenic cells in vivo in the two subsets of cells were significantly different and SSEA-1 cells. About 1:3 and 1:16 cells were able to grow in soft agar and as spheres in suspension, respectively (P < 0.001), and 1:80 cells were tumorigenic in vivo (P = 6×10 −8 ; Fig. 6a-d ). These results demonstrate that the cells responsible for tumour maintenance are a subpopulation of SSEA-1 + tumour cells that maintain a similar fibroblastic cellular nature as the cells that initiate the tumour, whereas their differentiated progeny is non-tumorigenic. We conclude that SSEA-1 + fibroblasts generated by in vitro transformation, similarly to CSCs, possess the ability to give rise and maintain hierarchically organized tumours.
Hierarchical organization of tumours induced by in vitrotransformed cells was confirmed in allotransplantation experiments using murine cells. BALB/c primary skin fibroblasts were transformed by introducing H-RasV12 and SV40 T antigens 28 and injected in BALB/cAnNCr-nu/nu mice. Similarly to human tumours, primary murine tumours contained a low number of tumorigenic cells (∼1:36,735), and tumour fibroblasts (∼5% of the tumour cell population) were enriched for clonogenic (∼1:28 versus ∼1:517 in the unsorted population, P < 0.001) and tumorigenic cells (∼1:1,056 versus ∼1 : 36,735, P = 2.9 × 10 −6 ; Supplementary Fig.  S6a-c) . As for human cells, SSEA-1 + cells were absent from primary mouse fibroblasts and appeared in the transformed population ( Supplementary Fig. S6d,e) . Unlike human SSEA-1 + fibroblasts, however, mouse SSEA-1 + fibroblasts did not generate SSEA-1 − progeny in vitro or in vivo, were not enriched in the tumourmaintaining fibroblastic population of primary tumours, and were not more clonogenic than SSEA-1 − cells ( Supplementary Fig. S6b ,f-i). These observations indicate that both human and mouse tumorigenic cells induced by in vitro transformation give rise to hierarchically organized tumours, but are characterized by different markers, in line with the notion that SSEA-1 marks different cell states in human and mouse 21 . Table S2 ). ∼230 genes were differentially expressed in all tumours in SSEA-1 + and SSEA-1 − cells (≥2-fold, P < 0.05; Fig. 6e and Supplementary Table S2 ). Importantly, 70% of these common genes were expressed at similar levels (P > 0.05, P < 2-fold) in SSEA-1 + tumour fibroblasts and in the SSEA-1 + transformed fibroblasts that were injected to induce primary tumours (Fig. 6f) . These results confirm that the tumour-maintaining SSEA-1 + cells retain a fibroblastic identity whereas their SSEA-1 − progeny acquire different cellular phenotypes. In line with differentiation and loss of tumorigenic potential, upregulated genes in SSEA-1 − cells included several regulators of differentiation and inhibitors of cellular proliferation, whereas genes promoting tumorigenesis, oncogenic microRNAs and negative regulators of differentiation were upregulated in SSEA-1 + tumour fibroblasts (Supplementary Table S2 ). fibroblasts that initiate primary tumours are indicative of their self-renewal capacity in vivo (Figs 6d,f and 5d-f). In addition, SSEA-1 + tumour fibroblasts from secondary tumours transplanted into new recipient mice formed tertiary tumours, indicating self-renewal over several passages (Fig. 7a) . At every passage, the percentage of SSEA-1 + cells in the tumours increased (∼3.1%, ∼7.9% and ∼25%, respectively; Fig. 7a,b) , and a higher abundance of SSEA-1 + cells correlated with a higher number of tumorigenic cells (∼1 : 3,759, ∼1 : 1,162 and ∼1 : 156, respectively), as assessed by colony formation in soft agar and by faster development of tumours (27, 13 and 11 days, respectively; Fig. 7a,c) . This result suggests evolution of SSEA-1 + tumour fibroblast cells over passages and selection of more aggressive cells, yet maintaining a hierarchical organization of tumours, a phenomenon described for several types of CSC (refs 29,30) .
Self-renewal and evolution of SSEA-1 + CSC-like cells in tumours
Taken together, these results demonstrate that in vitro-transformed SSEA-1 + fibroblasts have all the defining features of CSCs, including multipotency, self-renewal and the ability to generate hierarchically organized tumours by differentiating into phenotypically distinct, non-tumorigenic cells.
DISCUSSION
We show here that cells with CSC properties can be generated in vitro by oncogenic reprogramming of somatic cells. We find that, during in vitro transformation, a distinct subpopulation of cells arises that is responsible for tumour initiation and maintenance. These cells are marked by the presence of SSEA-1, have self-renewal potential, are multipotent and generate hierarchically organized tumours by differentiating into non-tumorigenic cells. SSEA-1 + CSC-like cells are molecularly distinct from SSEA-1 − cells in the population of transformed fibroblasts and from their differentiated progeny in tumours, in that they express a tumorigenic transcription programme, while repressing numerous tumour suppressors.
The CSC model postulates that CSCs may arise from either stem cells or progenitors, or may be generated from differentiated somatic cells through multiple mutagenic events 1, 19 . Whereas there is evidence, particularly from studies on haematological cancers, that CSCs can derive from tissue stem and progenitor cells 3, 4, 7, 8 , whether somatic cells can do so has been unclear. Our findings demonstrate that somatic cells possess enough plasticity to reprogramme and acquire CSC properties on oncogenic insults in vitro and may act as cells of origin of cancer.
Oncogenic reprogramming of differentiated cells into CSC-like cells seems to be a stochastic process within the population of in vitro-transformed cells, because, despite the presence of telomerase, H-RasV12 and SV40 T antigens in all fibroblasts, not all cells are equally tumorigenic and tumour formation is mainly driven by SSEA-1 + fibroblasts. Our observation that SSEA-1 − transformed fibroblasts can stochastically convert into SSEA-1 + cells and are able to induce inefficient tumour growth suggests a model where telomere maintenance, activation of an oncogene and inhibition of tumour suppressor pathways generate pre-malignant SSEA-1 − cells, which then develop, through further mutations or epigenetic changes, into malignant SSEA-1 + cells (Fig. 8 ). The reprogramming of differentiated cells into CSC-like cells during transformation is reminiscent of the de-differentiation of somatic cells into induced pluripotent stem (iPS) cells 31 . Interestingly, most reprogramming factors employed to induce iPS cells have been implicated in tumorigenesis [32] [33] [34] [35] [36] , indicating that reprogramming and cellular transformation might occur through related pathways. Moreover, inhibition of p53 enhances reprogramming of fibroblasts into iPS cells, although they are genetically unstable 37 . It is conceivable that, during transformation, normal pathways governing development and cell fate may be co-opted in the absence of functional tumoursuppressor mechanisms. De-differentiation of somatic cells into malignant stem cells or into normal pluripotent stem cells may thus represent different versions of similar reprogramming events.
Our ability to generate CSC-like cells in vitro will be a useful tool for the molecular characterization of CSCs. Whereas rare and heterogeneous CSC populations isolated from clinical samples cannot be easily characterized and manipulated, in vitro-generated CSC-like cells represent an experimentally amenable system that can be directly compared with its non-cancerous source. It will now be possible to interrogate pathways involved in acquisition and control of cellular selfrenewal in a targeted fashion and to characterize genetic and epigenetic events associated with CSC tumorigenicity, with the goal of uncovering new mechanisms of tumorigenesis and possible therapeutic targets. were generated essentially as described 18 from a primary skin fibroblast cell line (CRL-1474 from ATCC) and an hTERT-immortalized fibroblast cell line (gift of R. Faragher 38 ), respectively. Retroviral constructs expressing human telomerase, SV40 early region (LT and ST antigens) and oncogenic H-RasV12 were introduced serially. Retroviral supernatants were produced by transfecting amphotropic Phoenix cells (Orbigen) with pBABE-puro-hTERT, pBABE-zeo large T genomic or pBABE-neo-rasV12 (gifts of P. Adams). Infected cells were selected using puromycin (1 µg ml −1 , 2-3 days), zeocin (100 ng ml −1 , 7-10 days) or neomycin (1 mg ml −1 , 7 days), respectively. To transform cells under conditions of low infection efficiency, the three retroviral constructs were introduced simultaneously into primary fibroblasts using low-titre viruses so that ∼1:25,000 primary cells contained all three constructs. Four clonal populations were isolated after selection with puromycin, zeocin and neomycin. Primary and transformed fibroblasts were grown in MEM containing 15% fetal bovine serum (FBS), 2 mM l-glutamine, 100 U ml −1 penicillin and 100 µg ml −1 streptomycin. Primary skin fibroblasts isolated from 3-day-old BALB/c mice (gift of L. Li, US National Cancer Institute, NCI) were transformed by serially introducing retroviral constructs expressing SV40 T antigens and H-RasV12 as previously described 28 . Infected cells were selected with zeocin (0.4 mg ml −1 , 7 days) or neomycin (0.4 mg ml −1 , 7 days). Primary and transformed mouse fibroblasts were grown in DMEM containing 10% FBS, 2 mM l-glutamine, 100 U ml −1 penicillin and 100 µg ml −1 streptomycin. Primary mammary epithelial cells (Lonza) and in vitro-transformed mammary epithelial cells 24 were grown in an HMEC bullet kit (Lonza). All cells were grown at 37 • C in 5% CO 2 .
METHODS
Methods
Tumorigenicity assays. Six-week-old male immunodeficient mice (BALB/ cAnNCr-nu/nu from the Animal Production Program, NCI-Frederick, and NSG from The Jackson Laboratory) were maintained in pathogen-free conditions. For generation of primary tumours, transformed fibroblasts (3 × 10 6 , 3 × 10 5 or 3 × 10 3 per injection in 100 µl or 50 µl of PBS) were injected intradermally in BALB/cAnNCr-nu/nu mice. Tumour heterogeneity and differentiation of transformed fibroblasts were maximal when 3 × 10 3 cells were injected. To enhance engraftment efficiency, 2.97 × 10 5 hTERT-immortalized cells were used as carrier cells when 3×10 3 transformed fibroblasts were injected. For generation of secondary tumours in limiting-dilution experiments, primary tumours obtained from injections of 3 × 10 3 transformed fibroblasts were dissociated and graded numbers of tumour cells were resuspended in 50 µl of PBS containing 30% standard Matrigel (354234 BD Pharmingen). Cells were injected intradermally in NSG mice that had been locally shaved with a depilatory cream. Dead cells were removed from the tumour preparations by cell sorting using 7-amino-actinomycin D (7-AAD, BD Bioscience). Mice were monitored for up to 24 weeks after injection.
Tumour dissociation and fibroblast isolation. Tumours were removed surgically when they measured 1-1.5 cm in diameter, minced, incubated in a solution containing 1:10 diluted Liberase 3 (Roche), corresponding to 2.8 Collagenase Wunsch units ml −1 , and 0.2 mg ml −1 DNase (Roche) for 1 h at 37 • C, filtered through a 70 µm cell strainer and washed with sterile PBS. Typically, ∼70-80% dissociated cells were viable. Dissociated tumour cells were either sorted or plated to isolate tumour fibroblasts as previously described 39 . Briefly, dissociated tumour cells were plated in MEM containing 15% FBS, 2 mM l-glutamine, 100 U ml −1 penicillin and 100 µg ml −1 streptomycin for 18 h. Adherent cells were washed and grown for 3-7 days in the presence of 500 µg ml −1 neomycin to eliminate mouse stromal cells, in the absence of specific growth factors necessary for non-fibroblastic adherent cell types. Vimentin immunostaining was used to confirm substantial purity (>99%) of the isolated fibroblastic population. To isolate SSEA-1 + tumour fibroblasts, adherent cells were selected as described above either from SSEA-1 + -sorted tumour cells or from the unsorted population of tumour cells, as all tumour fibroblasts were positive for SSEA-1 + . For cell sorting, cultured transformed fibroblasts were stained with an anti-SSEA-1-Alexa 647 antibody and SSEA-1 + and SSEA-1 − cells were isolated using the FACSAria II flow cytometer. Sorted fibroblasts were plated for 16 h before injection. To sort viable, human SSEA-1 + and SSEA-1 − cells from xenograft-derived tumours, dissociated tumour cells were co-stained with anti-SSEA-1-Alexa 647 and biotin-conjugated anti-H-2K d major histocompatibility complex class I antibodies followed by secondary detection with Alexa 488-conjugated streptavidin (Invitrogen, 1:2,000), and 1.25 µg ml −1 7-AAD was added to the cells before sorting to identify dead cells. SSEA-1 + and SSEA-1 − cells in the 7-AAD − , H-K2 − d subpopulation of cells were sorted.
Soft-agar and non-adherent sphere-formation assays. Soft-agar assays were carried out as described 18 by plating 5,000 cells per well in six-well plates in 0.35% SeaPlaque Agar (Lonza) in MEM. For sphere formation, transformed cells were plated in Knockout DMEM (Invitrogen) supplemented with Knockout Serum Replacement (Invitrogen) in uncoated Petri dishes at clonogenic density (1,000 cells ml −1 ). Dead cells were removed from the tumour preparation by cell sorting using 7-AAD. hTERT-immortalized fibroblasts were used as negative controls for both assays.
Induction and quantitative analysis of transformed fibroblast differentiation.
Adipogenesis and osteogenesis were induced and quantitatively analysed as described 40 .
Immunohistochemistry and immunofluorescence. To detect SSEA-1 in cultured cells by immunofluorescence microscopy, cells were grown and stained on plastic plates as living cells, because fixation and growth on glass coverslips affected antigen detection. Immunodetection was carried out by incubating cells in medium containing an anti-SSEA-1 antibody (Millipore, 1:50) for 15 min at 37 • C, followed by addition of a secondary antibody and Hoechst 33342 at final concentrations of 20 µg ml −1 and 1.5 µg ml −1 , respectively, for a further 15 min at 37 • C. Cells were imaged on an Olympus IX70 inverted microscope using a ×10 or ×40 objective.
To detect asymmetrically divided cells, SSEA-1 + -sorted cells were plated at low density (∼1 cell per field using a ×10 objective) and incubated for 24-48 h before immunodetection. Pairs of cells whose nuclei were closer than 20 µm were considered to be cells originating from the same cell. Alternatively, SSEA-1 + -sorted cells were treated with 10 µM blebbistatin (Sigma) for 24 h as previously described 26 , trypsinized and seeded on poly-lysine-coated coverslips for 10 min before immunodetection. Blebbistatin-treated cells were imaged on a Zeiss META confocal microscope using a ×63 objective, acquiring 10-15 1-µm optical sections.
Lineage tracking. SSEA-1 + and SSEA-1 − cells were isolated by cell sorting from an unlabelled and a GFP-labelled version of the Transformed-2 cell line. The GFP-labelled cell line expresses an inducible form of GFP-lamin A that does not affect the tumorigenicity of the cells (P. Scaffidi, unpublished results). Tumours were surgically removed when they measured ∼1 cm in diameter. Half of the tumour was fixed in 4% PFA and embedded in paraffin for immunohistochemistry analysis and the other half was dissociated and analysed by flow cytometry.
Microarrays and quantitative analysis of gene expression. RNA from tumours was extracted by disrupting tumours in Trizol reagent (Invitrogen) as described 41 . RNA from cultured cells was extracted using the RNAeasy kit (Qiagen). Semiquantitative RT-PCR was carried out as described 42 with 21-29 cycles of amplification, depending on the target, to ensure detection of products in the linear range of amplification. Amplification products were loaded on 1.5% agarose gels and visualized using Syber Green (Invitrogen).Quantitative RT-PCR was carried out as described 40 . Primers used in this study are listed in Supplementary Table S3 . For microarray analysis, RNA was extracted from two biological replicates of SSEA-1 + and SSEA-1 − transformed fibroblasts isolated by cell sorting and from SSEA-1 + tumour fibroblasts and SSEA-1 − cells isolated from three primary tumours induced by 3,000 transformed fibroblasts. RNA labelling, hybridization on Affymetrix GeneChip Human Gene 1.0 ST arrays and data analysis were carried out by the Laboratory of Molecular Technology, SAIC-Frederick. Partek software was used to normalize and analyse the data. Genes showing at least a 1.5-fold difference between SSEA-1 + and SSEA-1 − transformed fibroblasts with P < 0.05
